What is the best adjuvant treatment for very young patients with medulloblastoma?

References

• Smith MA, Gurney JG, Linet M et al. (Eds). Cancer Incidence and Survival Among Children and Adolescents: United States SEER Program 1975–1995. National Cancer Institute, Bethesda, MD, USA (1999).
   Google Scholar
• Packer RJ, Sutton LN, Goldwein JW et al. Improved survival with the use of adjuvant chemotherapy in the treatment of medulloblastoma. J. Neurosurg.74, 433–440 (1991).
   PubMed Web of Science ®Google Scholar
• Cohen BH, Packer RJ, Siegel KR et al. Brain tumors in children under 2 years: treatment, survival, and long-term prognosis. Pediatr. Neurosurg.19, 171–179 (1993).
   PubMed Web of Science ®Google Scholar
• Kiltie A, Lashford L, Gattamaneni H. Survival and late effects in medulloblastoma patients treated with craniospinal irradiation under three years old. Med. Pediatr. Oncol.28, 348–354 (1997).
   PubMedGoogle Scholar
• Evans AE, Jenkin RDT, Sposto R et al. The treatment of medulloblastoma: the results of a prospective randomized trial of radiation therapy with and without chloroethylcyclohexyl nitrosourea, vincristine and prednisone. J. Neurosurg.72, 572–582 (1990).
   PubMed Web of Science ®Google Scholar
• Allon JC, Epstein F. Medulloblastoma and other primary malignant neuroectodermal tumor of the CNS: the effect of age and the extent of disease on prognosis. J. Neurosurg.57, 446–451 (1982).
   PubMed Web of Science ®Google Scholar
• Parwani AW, Stelow EB, Pambuccian SE et al. Atypical teratoid/rhabdoid tumor of the brain: cytopathologic characteristics and differential diagnosis. Cancer105(2), 65–70 (2005).
   PubMed Web of Science ®Google Scholar
• Saran FH, Driever PH, Thilmann C et al. Survival of very young children with medulloblastoma (primitive neuroectodermal tumor of the posterior fossa) treated with craniospinal irradiation. Int. J. Radiat. Oncol. Biol. Phys.42, 959–967 (1998).
   PubMed Web of Science ®Google Scholar
• Packer RJ, Gurney JG, Punyko JA et al. long-term neurologic and neurosensory sequelae in adult survivors of a childhood brain tumor: Childhood Cancer Survivor Study. J. Clin. Oncol.21(17), 3255–3261 (2003).
   PubMed Web of Science ®Google Scholar
• Johnson DL, McCabe MA, Nicholson HS et al. Quality of long-term survival in young children with medulloblastoma. J. Neurosurg.80, 1004–1010 (1994).
   PubMed Web of Science ®Google Scholar
• Palmer SL, Goloubeva O, Reddick WE et al. Patterns of intellectual development among survivors of pediatric medulloblastoma: a longitudinal analysis. J. Clin. Oncol.19, 2302–2308 (2001).
   PubMed Web of Science ®Google Scholar
• Ris MD, Packer R, Goldwein J et al. Intellectual outcome after reduced-dose radiation therapy plus adjuvant chemotherapy for medulloblastoma: a Children’s Cancer Group study. J. Clin. Oncol.19, 3470–3476 (2001).
   PubMed Web of Science ®Google Scholar
• Grill J, Renaux VK, Bulteau C et al. Long-term intellectual outcome in children with posterior fossa tumours according to radiation doses and volumes. Int. J. Radiat. Biol. Phys.45, 137–145 (1999).
   PubMed Web of Science ®Google Scholar
• Mulhern RK, Merchant TE, Gajjar A, Reddick WE, Kun LE. Late neurocognitive sequelae in survivors of brain tumours in childhood. Lancet Oncol.5, 399–408 (2005).
   Web of Science ®Google Scholar
• Silber JH, Radcliffe J, Peckham V et al. Whole-brain irradiation and decline in intelligence: the influence of dose and age on IQ score. J. Clin. Oncol.10, 1390–1396 (1992).
   PubMed Web of Science ®Google Scholar
• Staudt M, Schropp C, Staudt F et al. MRI assessment of myelination: an age standardization. Pediatr. Radiol.24, 122–127 (1994).
   Google Scholar
• Mulhern RK, Palmer SL, Reddick WE et al. Risks of young age for selected neurocognitive deficits in medulloblastoma are associated with white matter loss. J. Clin. Oncol.19, 472–479 (2001).
   PubMed Web of Science ®Google Scholar
• Walter AW, Mulhern RK, Gajjar A et al. Survival and neurodevelopmental outcome of young children with medulloblastoma at St Jude Children’s Research Hospital. J. Clin. Oncol.17, 3720–3728 (1999).
   PubMed Web of Science ®Google Scholar
• Mulhern RK, Palmer SL, Merchant TE et al. Neurocognitive consequences of risk-adapted therapy for childhood medulloblastoma. J. Clin. Oncol.23(24), 5511–5519 (2005).
   PubMed Web of Science ®Google Scholar
• Hoppe-Hirsch E, Brunet L, Laroussinie F et al. Intellectual outcome in children with malignant tumors of the posterior fossa: influence of the field of irradiation and quality of surgery. Childs Nerv. Syst.11, 340–345 (1995).
   PubMed Web of Science ®Google Scholar
• Ribi K, Relly C, Landolt MA, Alber FD, Boltshauser E, Grotzer MA. Outcome of medulloblastoma in children: long-term complications and quality of life. Neuropediatrics36(6), 357–365 (2005).
   PubMed Web of Science ®Google Scholar
• Lustig RH, Post SR, Srivannaboon K et al. Risk factors for the development of obesity in children surviving brain tumors. J. Clin. Endocrinol. Metab.88(2), 611–616 (2003).
   PubMed Web of Science ®Google Scholar
• Anderson DM, Rennie KM, Ziegler RS et al. Medical and neurocognitive late effects among survivors of childhood central nervous system tumors. Cancer92, 2709–2719 (2001).
   PubMed Web of Science ®Google Scholar
• Jakacki RI, Schramm CM, Donahue BR, Haas F, Allen JC. Restrictive lung disease following treatment for malignant brain tumors: a potential late effect of craniospinal irradiation. J. Clin. Oncol.13, 1478–1485 (1995).
   PubMed Web of Science ®Google Scholar
• Tait DM, Thorton-Jones H, Bloom HJG et al. Adjuvant chemotherapy for medulloblastoma: the first multi-centre control trial of the International Society of Paediatric Oncology (SIOP I). Eur. J. Cancer.26, 464–469 (1990).
   PubMed Web of Science ®Google Scholar
• Gilbertson RJ, Gajjar A. Molecular biology of medulloblastoma: will it ever make a difference to clinical management. J. Neurooncol.75, 273–278 (2005).
   PubMed Web of Science ®Google Scholar
• Schmandt S, Kuhl J. Chemotherapy as prophylaxis and treatment of meningiosis in children less than 3 years of age with medulloblastoma. J. Neurooncol.38, 187–192 (1998).
   PubMed Web of Science ®Google Scholar
• Kuhl J. Modern treatment strategies in medulloblastoma. Childs Nerv. Syst.14, 2–5 (1998).
   PubMed Web of Science ®Google Scholar
• Kretschmar CS, Tarbell NJ, Kupsky W et al. Pre-irradiation chemotherapy for infants and children with medulloblastoma: a preliminary report. J. Neurosurg.71(6), 820–825 (1989).
   PubMed Web of Science ®Google Scholar
• Duffner PK, Horowitz ME, Krischer JP et al. Postoperative chemotherapy and delayed radiation in children less than three years of age with malignant brain tumors. N. Engl. J. Med.328, 1725–1731 (1993).
   PubMed Web of Science ®Google Scholar
• Duffner PK, Horowitz ME, Krischer JP et al. The treatment of malignant brain tumors in infants and very young children: an update of the Pediatric Oncology Group experience. Neurooncol.1, 152–161 (1999).
   Google Scholar
• Goldwein JW, Radcliff J, Johnson J et al. Updated results of a pilot of low-dose carniospinal irradiation plus chemotherapy for children under five with cerebellar primitive neuroectodermal tumors (medulloblastoma). Int. J. Radiat. Oncol. Biol. Phys.34, 889–904 (1996).
   Google Scholar
• Jakacki RI, Feldman H, Jamison C et al. A pilot study of preirradiation chemotherapy and 1800 cGy craniospinal irradiation in young children with medulloblastoma. Int. J. Radiat. Oncol. Biol. Phys.60(2), 531–536 (2004).
   PubMed Web of Science ®Google Scholar
• Khalifa C, Hartmann O, Vassal G et al. High-dose busulfan and thitepa with autologous bone marrow transplantation in childhood malignant brain tumors: a Phase II study. Bone Marrow Transplant.9, 227–233 (1992).
   PubMed Web of Science ®Google Scholar
• Kalifa C, Grill J. The therapy of infantile malignant brain tumors: current status? J. Neurooncol.75, 279–285 (2005).
   PubMed Web of Science ®Google Scholar
• Finlay JL. The “head start” regimen for children less than 6 years of age newly-diagnosed with malignant brain tumors. J. Neurooncol.28, A68 (1996).
   Google Scholar
• Mason WP, Grovas A, Halpern S et al. Intensive chemotherapy and bone marrow rescue for young children with newly diagnosed malignant brain tumors. J. Clin. Oncol.16, 210–221 (1998).
   PubMed Web of Science ®Google Scholar
• Chi SN, Gardner S, Levy AS et al. Feasibility and response to induction chemotherapy intensified with high dose methotrexate for young children with newly diagnosed high risk disseminated medulloblastoma. J. Clin. Oncol.22, 4881–4887 (2004).
   PubMed Web of Science ®Google Scholar
• Perez-Martinez A, Quintero V, Gonzalez-Vincent M, Sevilla J, Diaz M, Madero L. High-dose chemotherapy with autologous stem cell rescue as first line of treatment in young children with medulloblastoma and supratentorial primitive neuroectodermal tumors. J. Neurooncol.67, 101–106 (2004).
   PubMed Web of Science ®Google Scholar
• Van Eys J, Cangir A, Coody D, Smith B. MOPP regimen as primary chemotherapy for brain tumors in infants. Neuro-oncol.3, 237–243 (1985).
   Web of Science ®Google Scholar
• Baram TZ, van Eys JV, Dowell RE et al. Survival and neurologic outcome of infants with medulloblastoma treated with surgery and MOPP chemotherapy; a preliminary report. Cancer60, 173–177 (1987).
   PubMed Web of Science ®Google Scholar
• Ater JL, van Eys J, Woo SY, Moore B 3rd, Copeland DR, Bruner J. MOPP chemotherapy without irradiation as primary postsurgical therapy for brain tumors in infants and young children. J. Neurooncol.32, 243–252 (1997).
   PubMed Web of Science ®Google Scholar
• Geyer JR, Zelzer PM, Boyett JM et al. Survival of infants with primitive neuroectodermal tumors or malignant ependymomas of the CNS treated with eight drugs in one day: a report from the Children’s Cancer Group. J. Clin. Oncol.12, 1607–1615 (1994).
   PubMed Web of Science ®Google Scholar
• White L, Kellie S, Gray E et al. Postoperative chemotherapy in children less than 4 years of age with malignant brain tumors: promising initial response to a VETOPEC-based regimen. A study of the Australian and New Zealand Children’s Cancer Study Group (ANZCCSG). J. Pediatr. Hematol. Oncol.20, 125–130 (1998).
   PubMed Web of Science ®Google Scholar
• Geyer JR, Sposto R, Jennings M et al. Multiagent chemotherapy and deferred radiotherapy in infants with malignant brain tumors: a report from the Children’s Cancer Group. J. Clin. Oncol.23(30), 7621–7631 (2005).
   PubMed Web of Science ®Google Scholar
• Rutkowski S, Bode U, Deinlein F et al. Treatment of early childhood medulloblastoma by postoperative chemotherapy alone. N. Engl. J. Med.352(10), 978–986 (2005).
   PubMed Web of Science ®Google Scholar
• Grill J, Sainte-Rose C, Jouvet A et al. Treatment of medulloblastoma with postoperative chemotherapy alone: an SFOP prospective trial in young children. Lancet Oncol.6(8), 573–580 (2005).
   PubMed Web of Science ®Google Scholar
• Schell MJ, McHaney VA, Green AA et al. Hearing loss in children and young adults receiving cisplatin with or without prior cranial irradiation. J. Clin. Oncol.7, 754–760 (1989).
   PubMed Web of Science ®Google Scholar
• Holm LE. Cancer occurring after radiotherapy and chemotherapy. Int. J. Radiat. Oncol. Biol. Phys.19, 1303–1308 (1990).
   PubMed Web of Science ®Google Scholar
• Tucker MA, D’Angio GJ, Boice JD et al. Bone sarcomas linked to radiotherapy and chemotherapy in children. N. Engl. J. Med.317, 588–593 (1987).
   PubMed Web of Science ®Google Scholar
• Fukunaga-Johnson N, Sandler HM, Marsh R et al. The use of 3D conformal radiotherapy (3D CRT) to spare the cochlea in patients with medulloblastoma. Int. J. Radiat. Oncol. Biol. Phys.41, 77–82 (1998).
   PubMed Web of Science ®Google Scholar
• Paulino AC, Narayana A, Mohideen MN et al. Posterior fossa boost in medulloblastoma: an analysis of dose to surrounding structures using 3-dimensional (conformal) radiotherapy. Int. J. Radiat. Oncol. Biol. Phys.46, 281–286 (2000).
   PubMed Web of Science ®Google Scholar
• Fukunaga-Johnson N, Lee JH, Sandler HM et al. Patterns of failure following treatment for medulloblastoma: is it necessary to treat the entire posterior fossa? Int. J. Radiat. Oncol. Biol. Phys.42(1), 143–146 (1998).
   PubMed Web of Science ®Google Scholar
• St Clair WH, Adams JA, Bues M et al. Advantage of protons compared to conventional x-ray or IMRT in the treatment of a pediatric patient with medulloblastoma. Int. J. Radiat. Oncol. Biol. Phys.58, 727–734 (2004).
   PubMed Web of Science ®Google Scholar
• Sure U, Berghorn WJ, Bertalanffy H et al. Staging, scoring and grading of medulloblastoma. A postoperative prognosis predicting system based on the cases of a single institute. Acta Neurochir. (Wien.)132(1–3), 59–65 (1995).
   PubMed Web of Science ®Google Scholar
• Ellison DW, Onilude OE, Lindsey JC et al. β-catenin status predicts a favorable outcome in childhood medulloblastoma: the United Kingdom Children’s Cancer Study Group Brain Tumour Committee. J. Clin. Oncol.23(31), 7951–7957 (2005).
   PubMed Web of Science ®Google Scholar
• Packer R, Cogen P, Vezina G et al. Medulloblastoma – clinical and biologic aspects. Neuro-oncol.1, 232–250 (1999).
   PubMedGoogle Scholar
• Gajjar A, Hernan R, Kocak M et al. Clinical, histopathological and molecular markers of prognosis: toward a new disease risk stratification system for medulloblastoma. J. Clin. Oncol.22(6), 984–993 (2004).
   PubMed Web of Science ®Google Scholar
• Grotzer M, Hogarty MD, Janss AJ et al. MYC messenger RNA expression predicts survival outcome in childhood primitive neuroectodermal tumor/medulloblastoma. Clin. Cancer Res.7, 2425–2433 (2001).
   PubMed Web of Science ®Google Scholar
• Grotzer M, Janss AJ, Fung K et al. TrkC expression predicts good clinical outcome in primitive neuroectodermal brain tumors. J. Clin. Oncol.18, 1027–1035 (2000).
   PubMed Web of Science ®Google Scholar
• Singh SK, Hawkins C, Clarke ID et al. Identification of human brain tumour initiating cells. Nature432(7015), 396–401 (2004).
   PubMed Web of Science ®Google Scholar
• Fan X, Matsui W, Khaki L et al. Notch pathway inhibition depletes stem-like cells and blocks engraftment in embryonal brain tumors. Cancer Res.66(15), 7445–7452 (2006).
   PubMed Web of Science ®Google Scholar